Cibisatamab

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Colorectal CancerMetastatic Colorectal Cancer

Phase 1

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

TerminatedNCT03866239

Hoffmann-La RocheColorectal Cancer

Start: 2019-05-07End: 2024-03-13Updated: 2024-08-09

Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

CompletedNCT04826003

Hoffmann-La RocheMetastatic Colorectal Cancer

Start: 2021-07-14End: 2024-11-11Updated: 2025-07-14

Related Papers

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

2026-04-20

Abstract CT105: FAP-targeted 4-1BBL trimeric costimulation amplifies T-cell activation and antitumor efficacy of a CEA-directed T-cell engager in MSS colorectal cancer

Cancer Research2026-04-17

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials.

2024-05-1528 citations